Home » CHIRON INITIATES SKIN CANCER DRUG TRIAL
CHIRON INITIATES SKIN CANCER DRUG TRIAL
Chiron has initiated a Phase I clinical trial of its investigational drug CHIR-265, a selective Raf kinase inhibitor, in patients with skin cancer.
The single-agent, open-label study is designed to evaluate the safety, dose tolerability and pharmacokinetic profile of CHIR-265 in patients with melanoma -- a type of skin cancer.
Preclinical data suggest that CHIR-265 has both direct anti-proliferative/pro-apoptotic activity on tumor cells as well as anti-angiogenic activity that targets the tumor blood supply.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May